Gibson, Dunn & Crutcher advised XOMA Corporation on the acquisition of an economic interest in DSUVIA, a sufentanil sublingual tablet, from Talphera Inc. for $8 million. The Gibson Dunn team was led by partner Ryan Murr.
Biotech & Pharmaceuticals
January 22, 2024, 1:24 PM